VINZENZ GRUPPE
     
 

Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.

Pinter, Matthias und Hucke, Florian und Graziadei, Ivo und Vogel, Wolfgang und Maieron, Andreas und Königsberg, Robert und Stauber, Rudolf und Grünberger, Birgit und Müller, Christian und Kölblinger, Claus und Peck-Radosavljevic, Markus und Sieghart, Wolfgang (2012) Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology, 263 (2). pp. 590-9. ISSN 1527-1315

Für diesen Eintrag wurde kein Volltext-Dokument angefügt.

Kurzfassung

PURPOSE To compare the efficacies of transarterial chemoembolization (TACE) and sorafenib in patients with advanced-stage hepatocellular carcinoma (HCC). MATERIALS AND METHODS The retrospective analysis of the data was approved by the institutional review board; the requirement to obtain informed consent was waived. Three hundred seventy-two patients with HCC were treated between January 1999 and December 2009. Patients with advanced HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging classification (Child-Pugh class A or B, Eastern Cooperative Oncology Group performance status of 1-2, and/or macrovascular invasion or extrahepatic metastasis) were included in the study (n = 97). Thirty-four patients underwent conventional TACE with doxorubicin plus lipiodol or TACE with drug-eluting beads; 63 patients were treated with sorafenib. RESULTS The median duration of sorafenib treatment was 4.6 months (95% confidence interval [CI]: 3.2, 6.0 months). The median number of TACE sessions per patient was 3 ± 2. Side effects of TACE and sorafenib were comparable to those reported in the literature. The median time to progression was similar between the two treatment groups (P = .737). The median overall survival was 9.2 months (95% CI: 6.1, 12.3 months) for patients treated with TACE and 7.4 months (95% CI: 5.6, 9.2 months) for those treated with sorafenib (P = .377). Only Child-Pugh class was associated with a better overall survival at uni- and multivariate analysis. CONCLUSION TACE achieved a promising outcome in select patients with advanced HCC (BCLC stage C).
Typ des Eintrags: Artikel
Bereiche: Ordensklinikum Linz Barmherzige Schwestern > Interne IV: Gastroenterologie & Hepatologie, Endokrinologie und Stoffwechsel, Ernährungsmedizin
Benutzer: Prof. Dr. Rainer Schöfl
Hinterlegungsdatum: 16 Nov 2021 11:40
Letzte Änderung: 17 Feb 2025 09:34
URI: https://eprints.vinzenzgruppe.at/id/eprint/9356
Aktionen (Anmeldung erforderlich)
Eintrag anzeigen
Eintrag anzeigen